Ameya Laboratories Ltd. Company History and Annual Growth Details

Our Company was incorporated in the year 1996 for manufacture of Bulk Active
Pharma Ingredients and Intermediates for drug molecules and was promoted by
Mr. K. Hari Babu. Mr. N.S. Walimbe joined as copromoter in the year 1997.

Our Company was not having its own manufacturing facilities initially and utilized
premises and production facilities of Dr. CurieÂs Labs Limited for a period of two
years till 1998 under leave and license agreement, which terminated in September,
1998. At this facility our Company manufactured 2,4 Dichloro 5 Fluoro Acetophenone
(DCFA) a drug intermediate for manufacture of Quinolones, which we supplied to
Dr. ReddyÂs Laboratories Limited and Aurobindo Pharma Limited.

In July 14, 1998 an agreement for sale was entered into by our Company with Andhra
Pradesh Industrial Development Corporation (APIDC) and Andhra Pradesh State
Financial Corporation (APSFC) to purchase land, buildings and plant & machinery of
M/s Jay Organics Limited situated at Survey No. 17, Chilakamarri Village, Shadnagar,
Mahboobnagar District, Andhra Pradesh under Section 29 of the SFC Act, 1952. M/s Jay
Organics Limited had defaulted in payment of loans to its lenders / these Corporations and
in exercise of power under Section 29 of the SFC Act, 1952, the lenders advertised the
sale of this unit and our Company offered to purchase this land, building and plant &
machineries for a total consideration of Rs. 40.40 lakhs. On acquisition of these facilities
we started our own manufacturing facilities.

Further with a view to add more products in our product profile we entered into contracts
in 2004 with Nitya Laboratories Limited for conversion jobs for manufacture of "Sodium
Methoxide or Sodium Methylate Solution & Powder" and "CIS (+) Hydroxy Lactum. Sodium
Methoxide and CIS Lactum contributed 9.73% and 24.27% respectively during nine months
period ended December 31, 2007 in our total sales. For details of contracts, please refer
to paragraph "Other Agreements" appearing on page number 95 of this Red Herring
Prospectus.

We are engaged in manufacture of Basic & Advanced Intermediates and fine chemicals
and are presently having manufacturing facilities for key intermediates like
2,4-Dichloro-5-Fluoro Acetophenone (DCFA) (an intermediate for synthesizing quinolone
antibiotics like ciprofloxacin); Chlorohexanone (key intermediate in the manufacture of
cardio vascular medicine) and Methyl-4 (4-Chloro 1 oxo butane) a, a Di-Methyl Acetate (an
intermediate in the manufacture of Fexofenadine an anti allergic drug). DCFA have
contributed 28.81% of our total sales during the nine months period ended December 31,
2007 whereas Methyl-4 (4-Chloro 1 oxo butane) a, a Di-Methyl Acetate contributed 24.54%
and Chlorohexanone contributed 8.95% of the total sales.

Our Company has a team of 25 chemists who are engaged in research and development.
Our in-house R&D team has manpower to handle complex molecular synthesis and operations.
Our Company has presence in custom synthesis and contract research which encompasses
process development and scaling up technologies in pilot plants. Our in-house R&D facilities
are recognized by Government of India, Department of Scientific & Industrial Research (DSIR),
which is at present valid till March 31, 2010. With continuous focus on research & development,
our in-house R&D team has been able to develop process for some of APIs / intermediates viz.
Diltiazem, Pentoxyfiline, Ciprofloxacin, Fexofenadine, Iopamidol and Naproxen.

Our Company has also been granted ISO 9001:2000 Certificate of Assessment by AQA
International LLC with a scope of design development, manufacture and supply of organic and
inorganic intermediates which is valid till December 30, 2008.

Our Company had started export of their products in the year 2002 to Israel followed by exports to
other countries like Italy, Japan, France, USA and Singapore. Currently, our exports comprise of
19.97% of our total turnover.

History and major events

Year Event

1996 -97 * Incorporation of AnuÂs Laboratories Limited for manufacturing of Bulk Drug
intermediates

* Started manufacturing in facility taken on leave and License basis.

* First Product manufactured -2,4 Dichloro 5 Fluoro Acetophenone (DCFA)

1998-99 * Purchased land, building, Plant & Machinery of a sick Unit through APSFC and
APIDC in a public bidding process

2001-02 * Introduced another major drug intermediate viz. Chlorohexanone

* Granted subsidy of Rs. 7.90 lakhs from Andhra Pradesh Pollution Control Board
as incentive for implementing projects for recovery of by-products and for
showing our commitment towards "Cleaner Production".

2002 -03 * Certified ISO 9001-2000 from AQA International to design development,
manufacture and supply of organic and inorganic intermediates

2004-05 * Introduced another drug intermediate Methyl-4(4-Chloro 1-Oxo butyl) a, a Di
Methyl Phenyl Acetate

2006-07 * Best Practices Award for Market penetration leadership from Frost and Sullivan
for the year 2005.

2008
-Anus Laboratories Ltd has recommended a Final Dividend of 15%.

2009

-Anu's Laboratories has given the Bonus in the Ratio of 1:1

-Company has splits its Face value of Shares from Rs 10 to Re 1

2010
Anu's Laboratories Ltd has informed BSE that the Company has acquired Stilbene Chemicals Ltd.

2011
- Anu's Laboratories Ltd has appointed Sri Chakravarthi Sundarashyam and Sri Ravindran Parthasarathy as Independent Directors on the Company's Board.

2013
-Company has changed its name from Anu's Laboratories Ltd to Ameya Laboratories Ltd.

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article